Stemirac’s 44 Million Yen Sales Within Expectations, Says Nipro President

Nipro President Yoshihiko Sano Nipro’s Stemirac, the first stem cell therapy for spinal cord injury conditionally approved in Japan late last year, generated sales of 44 million yen between its launch in May and the end of September, and President...read more